

Erratum

Montelukast Sodium combined with Erythromycin Cyclocarbonate shows promoting effects on Mycoplasma pneumoniae infection in children: Am J Transl Res. 2025; 17(1): 471-479

Tinglan Liu¹, Yixuan Shen², Yifan Liao¹

¹Department of Pharmacy, Dujiangyan Shoujia Hospital, Chengdu 611830, Sichuan, China; ²Department of Pharmacy, Northwest Women and Children's Hospital, Xi'an 710061, Shaanxi, China

Received September 2, 2025; Accepted September 10, 2025; Epub September 15, 2025; Published September 30, 2025

Some errors have been found in **Tables 2, 3, 6, and 7**. Therefore, we provide the correct versions to displace the original tables and reflect these changes. We sincerely apologize for this oversight and any confusion it may have caused. The correct **Tables 2, 3, 6, and 7** are provided below.

Address correspondence to: Tinglan Liu, Department of Pharmacy, Dujiangyan Shoujia Hospital, No. 88 Guanwen Road, Dujiangyan City, Chengdu 611830, Sichuan, China. Tel: +86-15198037871; E-mail: 15198037871@163.com

Table 2. Comparison of clinical efficacy between the two groups (n, %)

Group	n	Recovery	Remarkable effect	Effective	Ineffective	Total remarkable effect	Total effective
Control group	94	18 (19.15)	30 (31.91)	30 (31.91)	16 (17.02)	48 (51.06)	78 (82.97)
Research group	94	32 (34.04)	38 (40.43)	20 (21.28)	4 (4.26)	70 (74.47)	90 (95.75)
χ^2						11.016	8.057
P						0.001	0.045

Table 3. Comparison of the time for clinical symptoms to disappear between the two groups (n, $\bar{x} \pm s$)

Group	Fever resolution time (days)	Cough disappearance time (days)	Lung rales disappearance time (days)
Control group (n=94)	3.83±0.56	8.78±1.54	6.02±1.07
Research group (n=94)	3.25±0.66	6.83±1.49	4.48±1.18
t	-6.501	-8.823	-9.374
P	<0.001	<0.001	<0.001

Table 6. Comparison of the TAC and SOD levels between the two groups ($\bar{x} \pm s$)

Group	TAC (mmol/L)		SOD (U/mL)	
	Before treatment	After treatment	Before treatment	After treatment
Control group (n=94)	0.89±0.21	1.24±0.31 [#]	85.67±12.34	104.56±14.23 [#]
Research group (n=94)	0.91±0.22	1.56±0.35 [#]	86.34±12.45	125.78±16.34 [#]
t	0.638	6.636	0.371	9.495
P	0.525	<0.001	0.711	<0.001

Note: Compared to before treatment, [#]P<0.05. Capacity (TAC), superoxide dismutase (SOD).

Table 7. Comparison of the occurrence of adverse reactions between the two groups (n, %)

Group	n	Abdominal pain	Itching	Allergic purpura	Abnormal liver function	Palpitations	Abnormal blood routine	Loss of appetite	Total
Control group	94	4 (4.26)	4 (4.26)	4 (4.26)	0 (0.00)	2 (2.13)	4 (4.26)	0 (0.00)	18 (19.17)
Research group	94	0 (0.00)	2 (2.13)	2 (2.13)	0 (0.00)	0 (0.00)	0 (0.00)	0 (0.00)	4 (4.26)
χ^2									10.089
P									0.002